How Expert Module 2.4 and 2.6 Authoring Reduces Regulatory Risk — Intrinsik’s Proven Approach

High‑quality Module 2.4 and 2.6 summaries provide much greater value than simply restating nonclinical results. When authored by an experienced team, these modules provide a strategic scientific argument that supports clinical trial design, protects overall development timelines, and demonstrates regulatory readiness.

A strong Module 2.4 weaves pharmacology, safety pharmacology, pharmacokinetics, and toxicology data into an integrated narrative that highlights the pharmacological active dose range, target organs of toxicity, exposure margins, species relevance, reversibility of findings, and clinical implications. This overview is the lens regulators from various disciplines use to understand the Sponsor’s scientific reasoning and support for the planned clinical trial.

Module 2.6 strengthens the nonclinical narrative with comprehensive written and tabulated summaries. These sections further describe adverse findings and no-observed-adverse-effect levels (NOAEL) determinations, exposure comparability, cross‑species findings, and study limitations. They ensure the narrative aligns with the final study reports, which is expected by regulators, and they also provide an opportunity to include the Sponsor’s interpretation of any key issues that impact on safety.

Expert Module 2 authoring proactively addresses regulatory considerations such as target organ toxicities (and the extent of potential monitoring that is possible for human subjects/patients), impurity qualification, excipient justification, off‑target risks, formulation or lot differences, and analytical constraints. When not addressed, these factors are among the most common sources of information requests from regulators and clinical holds.

High‑quality nonclinical summaries also support the clinical narrative by bridging toxicology findings directly to human dose selection, dose escalation strategies, and clinical monitoring plans. These insights inform clinical risk management and increase regulator confidence in the overall development strategy.

Intrinsik’s Distinct Advantage

With decades of toxicology consulting and nonclinical authoring experience, Intrinsik is uniquely positioned to deliver purpose-built nonclinical Modules for Investigational New Drug (IND) and New Drug Application (NDA) submissions. Our capabilities include:

• Developing robust Module 2.4 overviews that tell a cohesive, regulator‑focused safety story.
• Authoring complete and accurate Module 2.6 summaries to provide detailed interpretation, cross‑study consistency, and transparent justification of findings.
• Aligning nonclinical messages across chemistry, manufacturing, and controls (CMC), drug metabolism and pharmacokinetics (DMPK), and clinical functions, ensuring the entire submission tells a consistent and scientifically supported story.
• Proactively identifying gaps and risks to reduce the likelihood of Agency information requests and delays in development timelines.
• Supporting strategic dossier planning, ensuring Modules 2.4 and 2.6 strengthen the overall submission package.

Intrinsik’s toxicology team includes scientists (MSc/PhD) and diplomats of the American Board of Toxicology with expertise in nonclinical authoring and strategic data compilation to provide Sponsors with high quality documents that improve regulatory reviewer confidence in support of the clinical program and overall development plan. Intrinsik’s knowledge and experience helps Sponsors avoid delays, reduce regulatory friction, and move forward with clarity and confidence.